<?xml version="1.0"?>
<Articles JournalTitle="Acta Medica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>61</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">A Review on Novel Methods of Pharmacology Teaching concerning Iranian Academic Context</title>
    <FirstPage>646</FirstPage>
    <LastPage>653</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Mahdi</FirstName>
        <LastName>Shooraj</LastName>
        <affiliation locale="en_US">Student Research Committee, Amol School of Paramedicine, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Kiarash</FirstName>
        <LastName>Fekri</LastName>
        <affiliation locale="en_US">Department of Preclinical, Amol Campus of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. AND Department of Paramedicine, Amol School of Paramedicine, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Noushin</FirstName>
        <LastName>Mousazadeh</LastName>
        <affiliation locale="en_US">Department of Nursing, Amol School of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Seif Ali</FirstName>
        <LastName>Mahdavi</LastName>
        <affiliation locale="en_US">Department of Preclinical, Amol Campus of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. AND Department of Paramedicine, Amol School of Paramedicine, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>07</Month>
        <Day>19</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>14</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">- Pharmacology is the cornerstone of health science courses the same as biomedical programs in educational setting. New educational intuitions and methodical progresses in teaching and learning, as well as recent findings in pharmacology research, can help pharmacology educators reconsider and regulate their teaching approaches. Thus, the aim of this article is to review existing studies on the different methods of teaching pharmacology and investigate different outcomes in this regard. In the present investigation, recent articles in the databases of Web of Science, PubMed, Scopus, Embase, Google Scholar, IranDoc and Scientific Information Database (SID) were examined, and the delegated documents were reviewed. The gathered data showed that students&#x2019; cognitive, metacognitive, and cooperative learning besides collaborative skills are effective factors for teaching. Additionally, application of blended learning or flipped instruction via technologies such as computer ameliorates the process of teaching and learning pharmacology in academic setting. Consequently, to overcome the difficulties in managing the data overload, it sounds necessary to introduce new teaching methods in academic context. Therefore, the current investigation is useful for practitioners, curriculum designers and educational administrators in medical and paramedical educational context.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/10739</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>61</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Upright Versus Recumbent Position in the Second Stage of Labor for Women With Epidural Analgesia: A Randomized Clinical Trial</title>
    <FirstPage>654</FirstPage>
    <LastPage>659</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Ali</FirstName>
        <LastName>Shahriari</LastName>
        <affiliation locale="en_US">Anesthesia, Critical Care and Pain Management Research Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Masoomeh</FirstName>
        <LastName>Nataj-Majd</LastName>
        <affiliation locale="en_US">Anesthesia, Critical Care and Pain Management Research Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Majid</FirstName>
        <LastName>Akrami</LastName>
        <affiliation locale="en_US">Anesthesia, Critical Care and Pain Management Research Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Khooshideh</LastName>
        <affiliation locale="en_US">Department of Obstetrics and Gynecology, Arash Women&#x2019;s Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mahsa</FirstName>
        <LastName>Soleimani</LastName>
        <affiliation locale="en_US">Department of Obstetrics and Gynecology, Arash Women&#x2019;s Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>21</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>27</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Epidural analgesia (EA) is an effective and common method of pain relief during labor. However, EA may also have some adverse effects like prolonged labor, increased risk of operative delivery, and some unwanted complications. It's unclear how maternal position affects the outcomes of natural birth with EA. This study aimed to compare mode of delivery and maternal and neonatal outcomes between recumbent and upright positions in nulliparous women with EA. This randomized clinical trial involved 540 women who received EA at cervical dilatation of 4 to 6 cm. During the second stage of labor, they were instructed to adopt upright or recumbent position. The main outcome was the mode of delivery. The secondary outcomes included duration of labor, pain intensity, the Apgar score, and other maternal and neonatal complications. Finally, 528 women were included in the final analysis. The upright group had a higher rate of cesarean section than the recumbent group. The duration of the labor stages did not differ between the groups. The pain intensity in the second stage was higher in the upright position. The Apgar score at 1 and 5 minutes was higher in the recumbent group. There was no difference in terms of other outcomes between the groups. Recumbent positions are beneficial in the case of rate of cesarean, mother&#x2019;s pain, and Apgar score in women with EA. So, adopting a recumbent position during the second stage of labor may be preferable for women with EA.
&#xD;

&#xA0;</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/11086</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>61</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Effect of Gestational Hypertension on Neonatal Hemoglobin Level</title>
    <FirstPage>660</FirstPage>
    <LastPage>666</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Parisa</FirstName>
        <LastName>Khosravi</LastName>
        <affiliation locale="en_US">Social Determinants of Health Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Soheila</FirstName>
        <LastName>Pirdadeh Beiranvand</LastName>
        <affiliation locale="en_US">Social Determinants of Health Research Center, School of Nursing and Midwifery, Lorestan University of Medical Sciences, Khorramabad, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Farzad</FirstName>
        <LastName>Ebrahimzadeh</LastName>
        <affiliation locale="en_US">Nutritional Health Research Center, School of Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Arefeh</FirstName>
        <LastName>Tadayon</LastName>
        <affiliation locale="en_US">1 Social Determinants of Health Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Hasani</LastName>
        <affiliation locale="en_US">Social Determinants of Health Research Center, School of Nursing and Midwifery, Lorestan University of Medical Sciences, Khorramabad, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>11</Month>
        <Day>24</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>17</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">This study aims to determine the effect of gestational hypertension on neonatal hemoglobin levels. This cohort study was performed on 150 pregnant women, 60 of whom had gestational hypertension and 90 were healthy. Participants were selected using sequential and quota non-probability sampling methods, respectively. The data were collected from interviews and examination forms. The newborns&#x2019; umbilical cords were clamped 30-60 sec after the delivery in both groups. Umbilical cord blood samples were taken to determine neonatal hemoglobin levels and sent to the laboratory immediately. Independent t-test was used to compare the two groups in terms of mean hemoglobin; general linear model with an identical link function was used to compare the two groups in terms of mean hemoglobin, considering the effect of confounding variables. SPSS software version 25 was used for the statistical analysis of the data. The statistical significance level in this study was considered to be 0.05. The mean neonatal hemoglobin level in women with gestational hypertension was significantly higher than that in the healthy group (16.73&#xB1;1.81 gr/dl vs. 15.56&#xB1;1.79, P&lt;0.001). This difference remained significant after adjusting for demographic and background variables as well as medical records of the participants (P=0.008). The results revealed the hemoglobin level of newborns of mothers who had gestational hypertension, was higher than newborns of healthy mothers. Therefore, performing proper screening tests and knowledge of the hemoglobin level in these infants routinely helps the healthcare staff to prevent, decide and provide more and more useful services.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/10882</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>61</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Erythrocyte Antioxidants and Hexokinase Activity Alterations in CCl4-Induced Cirrhotic Rats Through Naltrexone Treatment</title>
    <FirstPage>667</FirstPage>
    <LastPage>676</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Sarhadi kholari</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mitra</FirstName>
        <LastName>Nourbakhsh</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. AND Metabolic Disorders Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Golsa</FirstName>
        <LastName>Shekarkhar</LastName>
        <affiliation locale="en_US">Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran .</affiliation>
      </Author>
      <Author>
        <FirstName>Ahmad Reza</FirstName>
        <LastName>Dehpour</LastName>
        <affiliation locale="en_US">Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Abolfazl</FirstName>
        <LastName>Golestani</LastName>
        <affiliation locale="en_US">Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>01</Month>
        <Day>12</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>28</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Cirrhosis is the consequence of chronic liver injury Considering the crucial role of oxidative stress in the progression of liver cirrhosis, we aimed to investigate the ameliorative effect of NTX against oxidative stress in carbon tetrachloride (CCl4)-induced cirrhotic rats. Eighty-four male Wistar rats were randomly assigned into 4 groups (21 rats /group I) receiving CCl4; (II) NTX+CCl4; (III) mineral oil (M) (as the control); (IV) NTX+M. The animals in each group were sacrificed in 3 different time-points 2 weeks, 6 weeks (early cirrhosis) and 8 weeks (advanced cirrhosis). Liver function tests, NO metabolites, GSH level, as well as the activity of antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), glutathione peroxides (GPX), and hexokinase (HK) were assessed. NTX was able to ameliorate liver injury, revealed by attenuation of ALT activity, which was significantly enhanced due to cirrhosis induction, as well as pathological evaluation. HK was also increased significantly after treatment with CCl&#x2084; while NTX moderated this increase. Although CCl4 treatment did not have a significant effect on GSH levels, NTX was able to considerably increase GSH in blood. The activity of CAT and SOD as well as NO levels were all augmented by NTX in CCl4-treated rats. Naltrexone demonstrates antioxidative effects in liver cirrhosis and may confer a protective effect against hepatic cirrhosis through modulation of oxidative stress.
&#xD;


 
&#xD;

&#xA0;</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/9922</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/9922/5869</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>61</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Risk Factors and Etiological Classification of Ischemic Stroke Subtypes in Southwest Iran</title>
    <FirstPage>677</FirstPage>
    <LastPage>684</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Sara</FirstName>
        <LastName>Monjezi</LastName>
        <affiliation locale="en_US">Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Shahram</FirstName>
        <LastName>Rafie</LastName>
        <affiliation locale="en_US">Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ebrahim</FirstName>
        <LastName>Behzad</LastName>
        <affiliation locale="en_US">Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Shooka</FirstName>
        <LastName>Mohammadi</LastName>
        <affiliation locale="en_US">Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>06</Month>
        <Day>15</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Precise categorization of the causes of ischemic stroke (IS) is crucial for optimizing stroke treatment and assessing the prognosis of patients. This cross-sectional study aimed to determine the risk factors and various subcategories of IS in Iranian patients. The study included all patients with IS referred to Golestan Hospital (Ahvaz, Iran) for one year. Their demographics and clinical data were collected. The etiology of IS was classified based on the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria. A total of 1100 patients with IS were evaluated, 658 were male and 442 were female. They had an average age of 66 years (ranging between 20 and 99 years). The majority of them were in the 61-80 age group. The prevalence of risk factors for IS included hypertension (HTN) (71.4%), diabetes (50.4%), smoking (42.4%), history of previous stroke (28%), dyslipidemia (15.4%), and cardiovascular disease (22.5%). Three months after admission, the mortality rate was 10.7% and the majority of patients exhibited a lower level of disability based on the modified Rankin Score (mRS) compared to the time of admission. The frequency of all risk factors, except for HTN, differed significantly between genders (P&lt;0.05). Furthermore, the prevalence of risk factors varied significantly among different stroke etiologic subgroups (P&lt;0.05). The most common etiological factors identified by TOAST classification were associated with large artery atherosclerosis (LAA) and small artery occlusion (SAO). Significant variations were observed in the prevalence of different etiologic subtypes of stroke among genders and across different age groups.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/10955</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>61</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Evaluation of PHR160 Spray Effect on Improvement of Lung Function, Asthma Severity and Exacerbation in Severe Asthmatic Patients</title>
    <FirstPage>685</FirstPage>
    <LastPage>690</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Mehrdad</FirstName>
        <LastName>Dargahi-Malamir</LastName>
        <affiliation locale="en_US">Department of Pulmonology, Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Seyed Hamid</FirstName>
        <LastName>Borsi</LastName>
        <affiliation locale="en_US">Department of Pulmonology, Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Zahra</FirstName>
        <LastName>Mehraban</LastName>
        <affiliation locale="en_US">Department of Pulmonology, Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Kianizadeh</LastName>
        <affiliation locale="en_US">Department of Internal Medicine, Faculty of Medicine. Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Hoda</FirstName>
        <LastName>Mohsenikia</LastName>
        <affiliation locale="en_US">Department of Internal Medicine, Faculty of Medicine. Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>21</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>21</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Pinen Hydronoplacton Ribonucleic acid (PHR160) medicine contains compounds that can be useful in the recovery of respiratory patients. The aim of this study was to determine the effect of PHR spray on improving lung function, severity and asthma attacks in patients with severe asthma. This study is a pioneering interventional study (pilot study) conducted during the years 2021-2022 on patients with severe asthma resistant to treatment who referred to the lung clinic of Imam Khomeini, Golestan Hospitals and the private practice of lung specialists of this academic center. The study includes two groups of patients with asthma, both groups were given the usual treatment according to the stage of the disease, in addition, the intervention group was given two puffs of PHR spray every eight hours, and the control group was given a placebo spray with the same dose. Before and after the intervention, GSK 2002 questionnaire, six-minute walk distance (6MWD) and spirometry tests were completed. Among of 60 patients, 27 (45%) were male. The mean age of the patients was 44.33&#xB1;6.94 years. Based on findings, the forced vital capacity (FVC) and forced expiratory flow between 25% and 75% (FEF 25-75%) were significantly better in the intervention group than the control group (P&lt;0.001 and P=0.019, respectively), but there was a statistically remarkable difference between the two groups in terms of forced expiratory volume (FEV1) and FEV1/FVC (P=0.505, P=0.575, respectively). In addition, the GSK questionnaire score in the intervention group was higher than the control group (P&lt;0.001), however there is no significant difference between the two intervention groups in terms of the 6MWD test and the number of exacerbation (P=0.114 and P=0.09, respectively). It is generally concluded that PHR160 spray can lead to improvement of spirometry parameters and severity of disease in severe asthma patients by affecting small airways.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/10937</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>61</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Effects of Melatonme>
        <affiliation locale="en_US">Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mahdi</FirstName>
        <LastName>Sheykhi</LastName>
        <affiliation locale="en_US">Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Sogol</FirstName>
        <LastName>Alikarami</LastName>
        <affiliation locale="en_US">Pain Research Center, Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Abbas</FirstName>
        <LastName>Boosiraz</LastName>
        <affiliation locale="en_US">Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Seyed Ali</FirstName>
        <LastName>Dehghan Manshadi</LastName>
        <affiliation locale="en_US">Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Seyed Ahmad</FirstName>
        <LastName>Seyed Alinaghi</LastName>
        <affiliation locale="en_US">Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. AND Research Development Center, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Shayesteh</FirstName>
        <LastName>Jahanfar</LastName>
        <affiliation locale="en_US">Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, United States.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2025</Year>
        <Month>06</Month>
        <Day>22</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2025</Year>
        <Month>09</Month>
        <Day>06</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">People living with HIV increasingly participate as community health workers in supporting the HIV care continuum. Evidence suggests that peer interventions can reduce risky behaviors related to HIV transmission, provide relevant HIV education, and promote healthier lifestyles. In addition to HIV knowledge, peer supporters must be trained on their professional roles within clinical teams, appropriate boundaries, confidentiality practices, referral procedures, and self-care strategies in workplace settings. Conducting such studies in regions where peer interventions are underexplored can generate valuable insights and contribute to more precise reporting at both regional and international levels. A group of HIV-positive individuals, serving as peer supporters-non-clinical health advocates from within the affected community-were recruited after providing written informed consent and assurances of confidentiality. Eligibility required affirmative responses to two screening questions: "Are you willing to participate in this study?" and "Have you been serving as a peer supporter for more than six months?" A baseline survey was conducted to gather socio-demographic information (age, race/ethnicity, gender, education, prior work experience), assess HIV-related knowledge and understanding of peer roles, and document the specific activities peers perform. Additionally, data were collected on HIV self-care behaviors, including healthcare utilization, medication adherence, and risk-reduction practices. Knowledge domains included questions on viral life cycle, antiretroviral therapy and resistance, harm reduction strategies, and treatment adherence. Peer roles were assessed across various domains, including workplace expectations, boundaries, confidentiality, counselling, healthcare navigation, teamwork, communication with healthcare providers, peer readiness, and self-care. Communication skills were further evaluated based on stages of change, active listening, open-ended questioning, cultural awareness, and non-judgmental behaviors. A total of 7 participants (2 women [28.57%] and five men [71.42%]) were enrolled, with a mean age of 47.14 years. The mean duration since HIV diagnosis was approximately 12.19 years. Participants had an average peer work experience of about 9 months. All participants (100%) confirmed that peer supporters' involvement played a positive, essential role in patient diagnosis, support, and follow-up in HIV care. The findings of this study suggest that peer group involvement has a positive and significant impact on the process of HIV diagnosis, treatment, and follow-up care.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/11703</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/11703/5977</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>63</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2025</Year>
        <Month>11</Month>
        <Day>17</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Investigating the Analgesic Effect of Sublingual Glycerol Trinitrate (GTN) Spray as an Alternative Treatment in Renal Colic Pain: A Triple-Blinded Randomized Controlled Trial</title>
    <FirstPage>255</FirstPage>
    <LastPage>263</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Paria Sadat</FirstName>
        <LastName>Ramezany</LastName>
        <affiliation locale="en_US">Department of Emergency Medicine, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammed Ali</FirstName>
        <LastName>Shadram</LastName>
        <affiliation locale="en_US">Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Ahmad Reza</FirstName>
        <LastName>Dehpour</LastName>
        <affiliation locale="en_US">Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Razieh</FirstName>
        <LastName>Mohammad Jafari</LastName>
        <affiliation locale="en_US">Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Morteza</FirstName>
        <LastName>Saeedi</LastName>
        <affiliation locale="en_US">Department of Emergency Medicine, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mehrad</FirstName>
        <LastName>Aghili</LastName>
        <affiliation locale="en_US">Department of Emergency Medicine, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Javad</FirstName>
        <LastName>Seyedhosseini</LastName>
        <affiliation locale="en_US">Department of Emergency Medicine, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2025</Year>
        <Month>01</Month>
        <Day>04</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2025</Year>
        <Month>07</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Renal colic, a severe pain caused by renal and urethral calculi, causes millions of patients to visit the emergency department (ED) worldwide each year. Based on international guidelines, NSAIDs are the first-line analgesics of choice for renal colic management. The second most preferred analgesic is opioids. NSAIDs and opioids have several complications and contraindications that limit their administration and necessitate the search for alternative treatments for renal colic pain. The present study aimed to assess the effect of sublingual Glycerol Trinitrate (GTN) spray, a smooth muscle-relaxing agent, on renal colic pain as an alternative treatment. In this triple-blinded randomized controlled trial, 94 patients with renal colic who visited the emergency department (ED) were included. The drug group included 48 patients who were administered sublingual GTN spray, and the placebo group consisted of 46 patients. After diagnosis, the patients' pain was assessed based on the Numeric Rating Scale (NRS), a 30-milligram dose of ketorolac was administered to all patients, and sublingual GTN/placebo spray was administrated. The pain was also recorded 5 min after spray administration. Again, 30 min after spray administration, the NRS was reassessed. 94 patients enrolled in this study, the mean age of the participants was 39.22&#xB1;11.72, and 82 (87.23%) of them were male. Five minutes after GTN/placebo administration, The NRS in both groups decreased significantly compared with the NRS upon arrival (P&lt;0.01). Furthermore, in both groups, the NRS measured at 30 minutes also decreased significantly from the NRS measured at 5 minutes (P&lt;0.01). Nevertheless, the reduction in the NRS score between the drug and placebo groups was not significantly different (P=0.365). Our results showed no significant pain reduction with sublingual GTN spray in comparison with placebo; thus, sublingual GTN spray might not have considerable analgesic effects in patients with renal colic referred to the ED.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/11454</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/11454/5978</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>63</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2025</Year>
        <Month>11</Month>
        <Day>17</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Brain Tumor Presenting Mania Symptoms: A Case Report</title>
    <FirstPage>264</FirstPage>
    <LastPage>266</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Seyeh Hamzeh</FirstName>
        <LastName>Hosseini</LastName>
        <affiliation locale="en_US">Department of Psychiatry, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Hamed</FirstName>
        <LastName>Ghazvini</LastName>
        <affiliation locale="en_US">Department of Neuroscience, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Seyedeh Masoumeh</FirstName>
        <LastName>Seyedhosseini Tamijani</LastName>
        <affiliation locale="en_US">Department of Neuroscience, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Raheleh</FirstName>
        <LastName>Rafaiee</LastName>
        <affiliation locale="en_US">Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran .</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>08</Month>
        <Day>12</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2025</Year>
        <Month>07</Month>
        <Day>26</Day>
      </PubDa